GlobalData on MSN1d
Gilead and MSD to advance once-weekly HIV treatment to Phase III
The companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.
Success of long-lasting HIV drug hinges on pricing
Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...
News Medical2d
Affordability and supply remain critical to the success of long-lasting HIV drug
Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...
ENDPOINTS NEWS2d
Gilead, Mer­ck­'s ex­per­i­men­tal long-act­ing HIV treat­ment heads to Phase 3
Gilead and Merck said their once-weekly pill to treat HIV resulted in a comparable level of viral suppression compared to a ...
HIV cases rising in Alberta, sparking need for broad outreach, experts say
Doctors and front-line workers are watching closely as HIV rates increase significantly in Alberta.An annual Alberta Health ...
AllAfrica.com3d
South Africa: Alarming Rise in HIV Among Drug Users As Government Fails to Implement Policy
This has long been a problem in South Africa and appears to be getting worse. Research conducted in eThekwini in 2013 found that 17% of injecting drug users were HIV-positive. According to the new ...
Business Wire4d
Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapav…
Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...
Washington Blade4d
PrEP in transmasculine people
Historically, as mentioned, PrEP has been used to treat cisgender gay men, especially in light of the HIV crisis of the 1980s ...